Patients' characteristics and disease status at study entry. The 49 patients included in the study were sequentially attributed to treatment groups I to IV (see text and Table 2). Twenty-five patients had no measurable disease at study entry due to complete surgical resection. Prestudy treatments were: surgery (all patients, not shown); dacarbazine (DTIC); fotemustine (Fote); platinum (Pt); interferon-alpha (IFN-alpha); and isolated limb perfusion (ILP) without or with TNF-alpha (T), IFN-gamma (I) and/or Melphalan (M). Abbreviation: JWCI, John Wayne Cancer Institute.